Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Chronic Spontaneous Urticaria
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Article

July 21, 2008

NovaBay anounces details of dermatology program

Emeryville, Calif. - NovaBay Parmaceuticals announces it has successfully developed several formulations of Agonocide compounds for use in dermatology.

Emeryville, Calif.

- NovaBay Parmaceuticals announces it has successfully developed several formulations of Agonocide compounds for use in dermatology, according to iStockAnalysis.com.

One formulations, AgaDerm, delivers an Aganocide compound effectively when applied on the surface of the skin, and furthered penetration into hair follicles to treat fungal infections.

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!